Table of Contents

Retatrutide is among the newest weight-management drugs to capture headlines because it targets three hormone receptors. The glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors, gaining the nickname “Triple G.”

Weight loss with retatrutide happens gradually. Like other appetite- and metabolism-targeting medications, it requires a dose-escalation period to improve results while helping reduce side effects. Your timeline can also be influenced by factors like dosage, starting weight, genetics, lifestyle habits, consistency, and underlying health conditions. Even so, early clinical trials suggest retatrutide may produce greater weight loss than current treatments.

Below, we’ll discuss how long retatrutide may take to show noticeable weight-loss effects, what can affect your progress, and how to get the best possible results.

Key Takeaways

  • Higher doses (8 mg, 9 mg,  and 12 mg) consistently produced greater weight loss than lower doses, but they also require careful titration and monitoring.
  • By six months, double-digit losses are typical. Phase 2 data show about a 17-18% weight reduction at 24 weeks for the highest doses.
  • Phase 3 results reveal up to 28.7% mean loss at 68 weeks, with many participants achieving at least 25% or even 30% weight reductions.
  • Individual experiences vary widely. Some people see noticeable changes early, while others experience slower progress. Personal factors such as metabolism, lifestyle, health status, and adherence influence outcomes.
  • Diet, exercise, and behavioral support are essential during retatrutide therapy for long-term success.
  • Ongoing trials will determine whether the weight loss plateaus, continues, or requires maintenance strategies beyond 68 weeks.

Retatrutide weight loss timeline

The most reliable information on how long retatrutide takes to work comes from clinical trials, as it’s still an investigational drug and has not yet been approved for general use.

12 weeks

The early phase of retatrutide therapy involves titration. Participants generally start at 2 mg or 4 mg and increase the dose every four weeks.

A phase 1b study evaluated retatrutide in people with type 2 diabetes. The group receiving the highest escalating doses of 3/6/9/12 mg lost the most weight during the 12-week study. On average, participants in that group lost up to 8.96 kg (about 19.8 lbs) more than the placebo group.

24 weeks

The six-month point is the first major milestone. In a phase 2 obesity trial involving 338 adults, average weight loss after 24 weeks ranged from 7.2% with the 1 mg dose to 17.5% with the 12 mg dose. Participants taking the 8 mg dose lost an average of 17.3% of their body weight. In comparison, the placebo group lost just 1.6%.

To put that into perspective, someone starting at 220 lbs (100 kg) could lose about 16 lbs (7.2 kg) on the lower 1 mg dose, and nearly 39 lbs (17.5 kg) on the highest 12 mg dose in just 24 weeks. That means a person weighing 220 lbs could potentially drop to around 181 lbs in under six months based on the trial averages.

36 weeks

A phase 2 study focusing on type 2 diabetes assessed retatrutide doses of 0.5 mg, 4 mg, 8 mg, and 12 mg (with various escalation schedules) over 36 weeks.

According to an American Diabetes Association (ADA) meeting report, body weight loss of almost 17% was achieved with the 8 mg and 12 mg doses at week 36, and the data showed no plateau in weight reduction. This finding suggests that weight loss continues to progress between six and nine months, at least at higher doses.

48 weeks

By week 48, about 11 months into treatment, weight loss became even more significant. Participants lost an average of:

    • 8.7% of their body weight on the 1 mg dose,
    • 17.1% on 4 mg,
    • 22.8% on 8 mg,
    • 24.2% on 12 mg,
    • compared with just 2.1% in the placebo group.

That means someone starting at 220 lbs (100 kg) could lose about 53 lbs (24 kg) on the highest dose.

The study also showed that major weight-loss milestones were common at higher doses. In the 12 mg group, 93% lost at least 10% of their body weight, while 83% lost more than 15%. Participants taking retatrutide also saw major improvements in liver health, with liver fat dropping by as much as 86% in the highest-dose group.

68 weeks

Retatrutide’s first phase 3 trial (TRIUMPH-4) followed participants for 68 weeks, or about 16 months. The study included adults with obesity and knee osteoarthritis and tested 9 mg and 12 mg doses.

People taking the 12 mg dose lost an average of 28.7% of their body weight by week 68, while the 9 mg group lost 26.4%. For those on the 12 mg dose, this resulted in an average weight loss of 71.2 lbs (32.3 kg). In comparison, the placebo group lost 2.1%, or about 4.6 lbs.

Beyond the weight reduction, the trial reported impressive responder rates:

    • 58.6% of participants on 12 mg achieved at least 25% weight loss
    • 39.4% achieved at least 30% weight loss 

By comparison, only 1.3% of people in the placebo group lost 25% or more. These findings suggest that many people may continue losing weight beyond one year when retatrutide is combined with lifestyle changes. The study also found meaningful improvements in knee pain and physical function, showing benefits beyond weight loss alone.

Beyond 68 weeks

There is still limited data beyond 68 weeks because most retatrutide trials are ongoing. Current phase 3 studies are expected to finish in 2026. Early findings suggest that weight loss with retatrutide continues past 36 weeks and keeps increasing through at least 68 weeks, without clearly plateauing.

Longer-term studies will help determine how durable the results are and how to maintain weight loss if treatment is stopped or reduced.

Factors that affect retatrutide’s weight loss timeline

Woman in Sportswear Measures Waist with Tape Measure

Weight loss with retatrutide does not happen at the same pace for everyone. Several factors can influence how quickly results appear.

Dose and titration schedule

Retatrutide’s weight loss effect is dose-dependent because higher doses activate its target hormones more strongly. The drug works on three receptors, GLP-1, GIP, and glucagon, which help regulate appetite, fullness, blood sugar, and energy use. As the dose increases, these effects become more pronounced, often leading to greater reductions in hunger and calorie intake.

Clinical trials consistently showed that people taking higher doses lost more weight than those on lower doses. For example, lower doses produced modest weight loss of around 8%, while the 9 mg and 12 mg doses led to reductions of more than 20% in some studies. This pattern suggests that stronger receptor activation results in greater metabolic and appetite-related effects. 

Individual metabolism and baseline weight

People with a higher starting BMI or more body fat often lose more total weight in pounds or kilograms, even if their percentage of weight loss is similar to that of lighter individuals.

Factors like metabolism, genetics, and hormone responses can also affect how quickly someone responds to appetite-regulating drugs.

Researchers have identified more than 400 genes associated with obesity and weight gain. These genes can influence hunger, metabolism, cravings, and how fat is stored in the body. In some cases, genetics may also make it harder for certain people to lose weight, even when following low-calorie diets or staying physically active.

Lifestyle factors

Clinical trials do not rely on the medication alone. Participants also receive guidance on eating habits, physical activity, and behavior changes, which likely improve results.

People who increase protein intake, stay active, sleep well, manage stress, and consistently take their injections often lose weight faster and maintain progress more easily. In contrast, poor sleep, overeating, missed doses, and sedentary habits can slow results even while taking the drug. 

Health conditions and medications

Health conditions such as type 2 diabetes, PCOS, and hypothyroidism can slow weight loss, even with medications like retatrutide.

In clinical trials, people with type 2 diabetes still lost significant weight, but not as much as participants in obesity-only studies. Other medications can also affect results. Some drugs, including steroids and certain antidepressants, may promote weight gain, while treatments like metformin may support weight loss.

It’s important to review all medications and medical conditions with a healthcare provider before starting retatrutide.

How to get faster weight loss results with retatrutide

Here are strategies to support weight-loss success with retatrutide:

1. Be patient during the titration period

The first few weeks are about adjusting to the medication, and not immediate weight loss.  Expect minimal changes while the dose is low and your body adjusts. Side effects like nausea may appear, so work with your healthcare provider to manage them.

Don’t be discouraged if the scale doesn’t budge initially. Appetite suppression and behavioral changes often precede visible weight loss.

2. Prioritize balanced nutrition

Although retatrutide lowers appetite, food quality still strongly affects results. Eating enough protein helps reduce muscle loss during rapid weight reduction, while fiber-rich foods can improve fullness and reduce constipation, a common side effect.

Relying on ultra-processed or sugary foods may slow progress and make it harder to meet nutritional needs, especially since many people naturally eat less on the medication. Some users may also undereat without realizing it, leading to fatigue, weakness, hair loss, or nutrient deficiencies.

3. Stay physically active

Exercise complements pharmacologic weight loss by preserving muscle mass, boosting energy expenditure, and improving mood. Aim for a mix of aerobic activity (walking, cycling, swimming) and resistance training (weights, body-weight exercises). Activities that are enjoyable are more likely to become habits. Even modest daily movement can enhance the medication’s impact.

4. Monitor and celebrate milestones

Set realistic milestones such as a 5% weight-loss goal by month 3 or a 15% goal by month 6. Celebrate achievements along the way, including non-scale victories like improved stamina, better sleep, or reduced clothing sizes. Tracking progress helps maintain motivation during periods when the scale stalls.

5. Work closely with healthcare professionals

Your healthcare provider can gradually adjust your dose to help reduce side effects like nausea, vomiting, diarrhea, and constipation, which tend to become more common at higher doses. You may also need regular monitoring of blood sugar, kidney function, liver enzymes, heart rate, and signs of excessive weight loss or dehydration.

As your weight and blood sugar improve, your doctor may need to adjust other medications, especially diabetes or blood pressure treatments, to keep you safe throughout the process.

6. Be patient and flexible

Your experience with retatrutide may not look the same as someone else’s. Some people lose weight quickly, while others see slower but steady progress over time. If your results temporarily slow down, it does not necessarily mean the medication has stopped working. Factors like sleep, stress, food choices, physical activity, and consistency with injections can all affect progress.

Bottom line

Retatrutide weight loss timeline is gradual. The first few weeks are usually focused on adjusting to the medication, while noticeable appetite and weight changes often become more apparent after a few months. By six months to one year, many trial participants experienced substantial weight reduction, with average losses reaching about 24% at 48 weeks and nearly 29% at 68 weeks at higher doses.

The best results are typically seen when retatrutide is combined with better eating habits, regular movement, and ongoing medical guidance. Staying consistent and keeping realistic expectations can help long-term health improvements.

Frequently Asked Questions

No. Retatrutide is currently in phase 3 trials, and approval will depend on the completion and review of those studies.
Eligibility criteria in a Phase 3 obesity trial require adults with a body mass index (BMI) of at least 30 kg/m² or 27 kg/m² with at least one weight-related condition, such as high blood pressure, abnormal lipids, or obstructive sleep apnea. Trial criteria may change over time.
Yes. In a meta-analysis of retatrutide trials, participants receiving retatrutide had meaningful improvements in glycated hemoglobin (HbA1c), daily mean blood glucose, and fasting glucose compared with placebo. The same analysis found reductions in systolic and diastolic blood pressure and very-low-density lipoprotein cholesterol (VLDL), along with lower liver enzyme levels such as aspartate aminotransferase (AST). These findings suggest retatrutide may enhance cardiometabolic health in addition to lowering weight, although long-term data are still emerging.
Experience with similar GLP-1-based medications suggests that stopping pharmacotherapy often leads to weight regain. Ongoing retatrutide studies will determine whether maintenance dosing is needed to sustain results.
Body-composition data suggest that most of the weight lost on retatrutide is fat, but individual results vary. Some people lose more or less lean mass than others, likely influenced by diet, age, and physical activity.

Sources

Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., & Milicevic, Z. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet, 400(10366), 1869–1881. https://doi.org/10.1016/s0140-6736(22)02033-5

Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–Hormone-Receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/nejmoa2301972

Tsdevops. (2024, April 11). Phase 2 trial results demonstrate benefits of retatrutide in obesity, type 2 diabetes, NASH. ADA Meeting News. https://www.adameetingnews.org/phase-2-trial-results-demonstrate-benefits-of-retatrutide-in-obesity-type-2-diabetes-nash/

Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company. (n.d.). Eli Lilly and Company. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average

Pasqualotto E, Ferreira ROM, Chavez MP, Hohl A, Ronsoni MF, Pasqualotto T, Moraes FCA, Hespanhol L, Figueiredo Watanabe JM, Lütkemeyer C, van de Sande-Lee S. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabol Open. 2024 Sep 13;24:100321. doi: 10.1016/j.metop.2024.100321. PMID: 39318607; PMCID: PMC11420505.